QQQ   272.50 (+0.01%)
AAPL   458.73 (-0.28%)
MSFT   209.00 (+0.14%)
FB   260.50 (-0.31%)
GOOGL   1,512.35 (-0.28%)
AMZN   3,152.57 (-0.27%)
NVDA   461.87 (+0.91%)
CGC   17.29 (-0.17%)
BABA   252.65 (-0.42%)
TSLA   1,644.17 (+1.43%)
GE   6.65 (+0.76%)
MU   45.96 (-0.39%)
AMD   81.29 (-0.67%)
T   30.03 (+0.40%)
F   7.07 (+0.57%)
ACB   10.72 (+5.30%)
GILD   68.64 (+0.67%)
NFLX   483.84 (+0.52%)
DIS   130.38 (-0.44%)
BAC   26.53 (+0.68%)
BA   177.19 (+1.41%)
QQQ   272.50 (+0.01%)
AAPL   458.73 (-0.28%)
MSFT   209.00 (+0.14%)
FB   260.50 (-0.31%)
GOOGL   1,512.35 (-0.28%)
AMZN   3,152.57 (-0.27%)
NVDA   461.87 (+0.91%)
CGC   17.29 (-0.17%)
BABA   252.65 (-0.42%)
TSLA   1,644.17 (+1.43%)
GE   6.65 (+0.76%)
MU   45.96 (-0.39%)
AMD   81.29 (-0.67%)
T   30.03 (+0.40%)
F   7.07 (+0.57%)
ACB   10.72 (+5.30%)
GILD   68.64 (+0.67%)
NFLX   483.84 (+0.52%)
DIS   130.38 (-0.44%)
BAC   26.53 (+0.68%)
BA   177.19 (+1.41%)
QQQ   272.50 (+0.01%)
AAPL   458.73 (-0.28%)
MSFT   209.00 (+0.14%)
FB   260.50 (-0.31%)
GOOGL   1,512.35 (-0.28%)
AMZN   3,152.57 (-0.27%)
NVDA   461.87 (+0.91%)
CGC   17.29 (-0.17%)
BABA   252.65 (-0.42%)
TSLA   1,644.17 (+1.43%)
GE   6.65 (+0.76%)
MU   45.96 (-0.39%)
AMD   81.29 (-0.67%)
T   30.03 (+0.40%)
F   7.07 (+0.57%)
ACB   10.72 (+5.30%)
GILD   68.64 (+0.67%)
NFLX   483.84 (+0.52%)
DIS   130.38 (-0.44%)
BAC   26.53 (+0.68%)
BA   177.19 (+1.41%)
QQQ   272.50 (+0.01%)
AAPL   458.73 (-0.28%)
MSFT   209.00 (+0.14%)
FB   260.50 (-0.31%)
GOOGL   1,512.35 (-0.28%)
AMZN   3,152.57 (-0.27%)
NVDA   461.87 (+0.91%)
CGC   17.29 (-0.17%)
BABA   252.65 (-0.42%)
TSLA   1,644.17 (+1.43%)
GE   6.65 (+0.76%)
MU   45.96 (-0.39%)
AMD   81.29 (-0.67%)
T   30.03 (+0.40%)
F   7.07 (+0.57%)
ACB   10.72 (+5.30%)
GILD   68.64 (+0.67%)
NFLX   483.84 (+0.52%)
DIS   130.38 (-0.44%)
BAC   26.53 (+0.68%)
BA   177.19 (+1.41%)
Log in

NASDAQ:REGNRegeneron Pharmaceuticals Stock Price, Forecast & News

$615.55
+4.66 (+0.76 %)
(As of 08/14/2020 01:12 PM ET)
Add
Compare
Today's Range
$610.55
Now: $615.55
$617.00
50-Day Range
$598.86
MA: $625.57
$658.21
52-Week Range
$271.37
Now: $615.55
$664.64
Volume7,422 shs
Average Volume1.22 million shs
Market Capitalization$67.72 billion
P/E Ratio23.83
Dividend YieldN/A
Beta0.56
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi, Bayer, Teva, Mitsubishi Tanabe Pharma, Alnylam Pharmaceuticals, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Read More
Regeneron Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.56 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:REGN
CUSIP75886F10
Phone914-847-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.86 billion
Cash Flow$24.04 per share
Book Value$100.56 per share

Profitability

Net Income$2.12 billion

Miscellaneous

Employees8,100
Market Cap$67.72 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$615.55
+4.66 (+0.76 %)
(As of 08/14/2020 01:12 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive REGN News and Ratings via Email

Sign-up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Regeneron Pharmaceuticals (NASDAQ:REGN) Frequently Asked Questions

How has Regeneron Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Regeneron Pharmaceuticals' stock was trading at $464.70 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, REGN stock has increased by 32.5% and is now trading at $615.55.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Regeneron Pharmaceuticals?

27 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 11 hold ratings, 15 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Regeneron Pharmaceuticals
.

When is Regeneron Pharmaceuticals' next earnings date?

Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Regeneron Pharmaceuticals
.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced its quarterly earnings results on Wednesday, August, 5th. The biopharmaceutical company reported $7.16 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $5.59 by $1.57. The biopharmaceutical company earned $1.95 billion during the quarter, compared to analysts' expectations of $1.74 billion. Regeneron Pharmaceuticals had a return on equity of 26.71% and a net margin of 37.30%. The company's revenue for the quarter was up 23.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $6.02 EPS.
View Regeneron Pharmaceuticals' earnings history
.

How will Regeneron Pharmaceuticals' stock buyback program work?

Regeneron Pharmaceuticals declared that its Board of Directors has approved a share repurchase program on Tuesday, November 5th 2019, which authorizes the company to repurchase $1,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to purchase up to 2.9% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company's board of directors believes its shares are undervalued.

What price target have analysts set for REGN?

27 brokers have issued 12 month price objectives for Regeneron Pharmaceuticals' stock. Their forecasts range from $325.00 to $800.00. On average, they anticipate Regeneron Pharmaceuticals' share price to reach $592.78 in the next year. This suggests that the stock has a possible downside of 3.7%.
View analysts' price targets for Regeneron Pharmaceuticals
.

Has Regeneron Pharmaceuticals been receiving favorable news coverage?

News stories about REGN stock have trended somewhat negative on Friday, InfoTrie reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Regeneron Pharmaceuticals earned a news impact score of -1.6 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days.
View the latest news about Regeneron Pharmaceuticals
.

Are investors shorting Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals saw a drop in short interest in the month of June. As of June 30th, there was short interest totaling 2,120,000 shares, a drop of 14.2% from the June 15th total of 2,470,000 shares. Based on an average daily volume of 1,370,000 shares, the short-interest ratio is currently 1.5 days. Approximately 2.0% of the company's stock are sold short.
View Regeneron Pharmaceuticals' Short Interest
.

Who are some of Regeneron Pharmaceuticals' key competitors?

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Johnson & Johnson (JNJ), Micron Technology (MU), Walt Disney (DIS), Visa (V) and Intel (INTC).

Who are Regeneron Pharmaceuticals' key executives?

Regeneron Pharmaceuticals' management team includes the following people:
  • Dr. Schleifer Leonard S., Co-Founder, Pres, CEO & Exec. Director (Age 66)
  • Dr. George D. Yancopoulos, Founding Scientist, Pres, Chief Scientific Officer & Director (Age 59)
  • Mr. Robert E. Landry Jr., Exec. VP of Fin. & CFO (Age 55)
  • Mr. Daniel P. Van Plew, Exec. VP and GM of Industrial Operations & Product Supply (Age 46)
  • Ms. Marion E. McCourt, Sr. VP & Head of Commercial (Age 59)

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (11.33%), Vanguard Group Inc. (7.13%), California Public Employees Retirement System (0.76%), Bank of New York Mellon Corp (0.70%), FIL Ltd (0.51%) and Sumitomo Mitsui Trust Holdings Inc. (0.44%). Company insiders that own Regeneron Pharmaceuticals stock include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry and Sanofi.
View institutional ownership trends for Regeneron Pharmaceuticals
.

Which major investors are selling Regeneron Pharmaceuticals stock?

REGN stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Candriam Luxembourg S.C.A., LSV Asset Management, Toronto Dominion Bank, Bank of Nova Scotia, Advisor Group Holdings Inc., NN Investment Partners Holdings N.V., and NN Investment Partners Holdings N.V.. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry, and Sanofi.
View insider buying and selling activity for Regeneron Pharmaceuticals
.

Which major investors are buying Regeneron Pharmaceuticals stock?

REGN stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Vanguard Group Inc., California Public Employees Retirement System, APG Asset Management N.V., Swiss National Bank, Bank of New York Mellon Corp, Robeco Institutional Asset Management B.V., and First Trust Advisors LP.
View insider buying and selling activity for Regeneron Pharmaceuticals
.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Regeneron Pharmaceuticals' stock price today?

One share of REGN stock can currently be purchased for approximately $615.55.

How big of a company is Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals has a market capitalization of $67.72 billion and generates $7.86 billion in revenue each year. The biopharmaceutical company earns $2.12 billion in net income (profit) each year or $21.47 on an earnings per share basis. Regeneron Pharmaceuticals employs 8,100 workers across the globe.

What is Regeneron Pharmaceuticals' official website?

The official website for Regeneron Pharmaceuticals is www.regeneron.com.

How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.